Microbot Medical director granted 10,000 stock options

Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock.

Rhea-AI Filing Summary

Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.

Insights

Equity compensation analyst

Director received 10,000 stock options at a $2.37 strike as routine equity compensation.

Director Wenderow Tal Baruch was granted stock options for 10,000 shares of Microbot Medical common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. This is classified as a grant or award acquisition rather than a market trade.

The filing shows no open-market buying or selling, only this equity award. After the grant, Baruch’s reported derivative holdings consist of these 10,000 options. As a standard director compensation event, this appears routine and carries limited signaling value for near-term stock expectations.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Wenderow Tal Baruch

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 contracts (Direct)

Key Figures

Option grant size: 10,000 options Exercise price: $2.37 per share Underlying shares: 10,000 shares +2 more

5 metrics

Option grant size 10,000 options Stock Option (Right to Buy) granted to director

Exercise price $2.37 per share Conversion or exercise price of options

Underlying shares 10,000 shares Common stock underlying the options

Expiration date April 1, 2036 Options expiration date

Post-grant derivative holdings 10,000 options Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, par value $0.01 per share

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock, par value $0.01 per share financial

"underlying_security_title: "Common Stock, par value $0.01 per share""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Microbot Medical (MBOT) report in this Form 4?

Microbot Medical reported that director Wenderow Tal Baruch received a grant of stock options for 10,000 shares of common stock. These options were awarded at a $2.37 exercise price per share as equity compensation, not as an open-market stock purchase or sale.

At what price can the new stock options for MBOT be exercised?

The granted options allow purchase of Microbot Medical common stock at an exercise price of $2.37 per share. This means the director can buy up to 10,000 shares at $2.37, regardless of future market price, until the options’ expiration date in 2036.

How many Microbot Medical shares are covered by the new option grant?

The new stock option grant to director Wenderow Tal Baruch covers 10,000 underlying shares of Microbot Medical common stock. Following this award, the Form 4 shows total derivative holdings for Baruch of options representing 10,000 shares, all held directly.

When do the newly granted Microbot Medical stock options expire?

The granted stock options to director Wenderow Tal Baruch expire on April 1, 2036. Until that expiration date, the director has the right to buy up to 10,000 Microbot Medical common shares at the fixed exercise price of $2.37 per share.

Was this MBOT Form 4 an open-market buy or sell of shares?

No, the Form 4 reports a grant, award, or other acquisition of stock options, not an open-market trade. Director Wenderow Tal Baruch received options for 10,000 shares at a $2.37 strike price as compensation, with no reported buying or selling of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wenderow Tal Baruch

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MASSACHUSETTS 02043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.37	04/01/2026		A		10,000		04/01/2026	04/01/2036	Common Stock, par value $0.01 per share	10,000	$0	10,000	D

Explanation of Responses:

	/s/ Tal Wenderow	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)